Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The pioneering role of GATA2 in androgen receptor variant regulation is controlled by bromodomain and extraterminal proteins in castrate-resistant prostate cancer.

Chaytor L, Simcock M, Nakjang S, Heath R, Walker L, Robson C, Jones D, Gaughan L.

Mol Cancer Res. 2019 Mar 4. pii: molcanres.1231.2018. doi: 10.1158/1541-7786.MCR-18-1231. [Epub ahead of print]

PMID:
30833300
2.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G.

Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.

PMID:
29936064
3.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P.

Blood. 2016 Jul 28;128(4):497-503. doi: 10.1182/blood-2016-02-700872. Epub 2016 May 25.

4.

Clinical implications of distinct metastasizing preferences of different melanoma subtypes.

Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, Scherrer E, Holzmann D, Dummer R.

Eur J Dermatol. 2014 Mar-Apr;24(2):236-41. doi: 10.1684/ejd.2014.2292.

PMID:
24721680
5.

Taxonomic classification of phytoplankton with multivariate optical computing, part I: design and theoretical performance of multivariate optical elements.

Swanstrom JA, Bruckman LS, Pearl MR, Simcock MN, Donaldson KA, Richardson TL, Shaw TJ, Myrick ML.

Appl Spectrosc. 2013 Jun;67(6):620-9. doi: 10.1366/12-06783.

PMID:
23735247
6.

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.

Schoenewolf NL, Dummer R, Mihic-Probst D, Moch H, Simcock M, Ochsenbein A, Gillessen S, Schraml P, von Moos R; Swiss Group for Clinical Cancer Research (SAKK).

Case Rep Oncol. 2012 May;5(2):280-9. doi: 10.1159/000339300. Epub 2012 Jun 5.

7.

Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).

Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, Studer G, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2012 Aug;104(2):213-8. Epub 2012 Jun 21.

PMID:
22726581
8.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2013 Jan;14(1):34-9. doi: 10.1016/j.cllc.2012.04.001. Epub 2012 May 24.

PMID:
22633220
9.

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.

Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.

Oncol Rep. 2012 Aug;28(2):654-8. doi: 10.3892/or.2012.1826. Epub 2012 May 18.

PMID:
22614944
10.

High dose-rate versus low dose-rate brachytherapy for lip cancer.

Ghadjar P, Bojaxhiu B, Simcock M, Terribilini D, Isaak B, Gut P, Wolfensberger P, Brömme JO, Geretschläger A, Behrensmeier F, Pica A, Aebersold DM.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1205-12. doi: 10.1016/j.ijrobp.2011.09.038. Epub 2011 Nov 16.

PMID:
22099044
11.

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).

Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2012 Jun;23(6):1474-81. doi: 10.1093/annonc/mdr448. Epub 2011 Oct 14.

PMID:
22003243
12.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28.

13.

Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).

Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16.

PMID:
21300466
14.

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Madlung A, Simcock M, Ghadjar P.

Cancer. 2011 Aug 1;117(15):3532; author reply 3532-3. doi: 10.1002/cncr.25949. Epub 2011 Feb 1. No abstract available.

15.

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.

Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A.

J Clin Oncol. 2011 Jan 20;29(3):303-9. doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13.

PMID:
21149672
16.

Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).

von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R.

Onkologie. 2010;33(6):295-9. doi: 10.1159/000313598. Epub 2010 May 14.

PMID:
20523092
17.

Incidence of small lymph node metastases with evidence of extracapsular extension: clinical implications in patients with head and neck squamous cell carcinoma.

Ghadjar P, Simcock M, Schreiber-Facklam H, Zimmer Y, Gräter R, Evers C, Arnold A, Wilkens L, Aebersold DM.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1366-72. doi: 10.1016/j.ijrobp.2009.09.043. Epub 2010 Mar 16.

PMID:
20231070
18.

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G.

Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.

19.

Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma.

Ghadjar P, Schreiber-Facklam H, Gräter R, Evers C, Simcock M, Geretschläger A, Blumstein NM, Zbären P, Zimmer Y, Wilkens L, Aebersold DM.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1127-32. doi: 10.1016/j.ijrobp.2009.03.065. Epub 2009 Aug 3.

PMID:
19647955
20.

MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers.

Ghadjar P, Blank-Liss W, Simcock M, Hegyi I, Beer KT, Moch H, Aebersold DM, Zimmer Y.

Clin Exp Metastasis. 2009;26(7):809-15. doi: 10.1007/s10585-009-9280-9. Epub 2009 Jul 29.

21.

A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.

Hitz F, Martinelli G, Zucca E, von Moos R, Mingrone W, Simcock M, Peterson J, Cogliatti SB, Bertoni F, Zimmermann DR, Ghielmini M; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.

Hematol Oncol. 2009 Sep;27(3):154-9. doi: 10.1002/hon.891.

PMID:
19274614
22.

Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.

Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(8):1077-82.

PMID:
19195333
23.

Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).

Zenhäusern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A; Swiss Group for Clinical Cancer Research (SAKK).

Haematologica. 2008 Sep;93(9):1426-8. doi: 10.3324/haematol.11564. Epub 2008 Jul 4. No abstract available.

24.

Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.

Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(8):1165-73.

PMID:
18240857
25.

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):931-9.

PMID:
17926647
26.

TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents.

Laifer G, Widmer AF, Simcock M, Bassetti S, Trampuz A, Frei R, Tamm M, Battegay M, Fluckiger U.

Am J Med. 2007 Apr;120(4):350-6.

PMID:
17398230
27.

Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study.

Mettler J, Simcock M, Sendi P, Widmer AF, Bingisser R, Battegay M, Fluckiger U, Bassetti S.

BMC Infect Dis. 2007 Mar 26;7:21.

28.

A smoking cessation programme in HIV-infected individuals: a pilot study.

Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher HC, Spirig R, Battegay M; Swiss HIV Cohort Study.

Antivir Ther. 2006;11(6):787-95.

PMID:
17310823
29.

Precision in imaging multivariate optical computing.

Simcock MN, Myrick ML.

Appl Opt. 2007 Mar 1;46(7):1066-80.

PMID:
17304305
30.

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M; Swiss HIV Cohort Study.

PLoS One. 2007 Jan 24;2(1):e173.

31.

Tuning D* with modified thermal detectors.

Simcock MN, Myrick ML.

Appl Spectrosc. 2006 Dec;60(12):1469-76.

PMID:
17217598
32.

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?

Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2006;11(3):305-14.

PMID:
16759046
33.

Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies.

Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, Buitrago C, Sonnet S, Gratwohl A, Passweg J, Fluckiger U.

Clin Infect Dis. 2005 Oct 15;41(8):1143-9. Epub 2005 Sep 12.

PMID:
16163633
34.

Predictors of recurrent hyperparathyroidism after total parathyroidectomy in chronic renal failure.

Stratton J, Simcock M, Thompson H, Farrington K.

Nephron Clin Pract. 2003;95(1):c15-22.

PMID:
14520017
35.

Prescribing of oral contraceptives to minors.

Simcock MJ.

Med J Aust. 1972 Jan 15;1(3):140-1. No abstract available.

PMID:
5060479
36.

The technique of suction evacuation of the uterus.

Simcock MJ.

Med J Aust. 1971 Mar 27;1(13):674-6. No abstract available.

PMID:
5553812
37.

Bupivacaine for regional analgesia in labour. A double-blind comparison with lignocaine.

Simcock MJ.

Med J Aust. 1970 May 2;1(18):889-91. No abstract available.

PMID:
5428140
38.

Pregnancy is cholestatic.

Simcock MJ, Forster FM.

Med J Aust. 1967 Nov 25;2(22):971-3. No abstract available.

PMID:
6081087
39.

Addison's disease in pregnancy.

Simcock MJ.

Med J Aust. 1966 Feb 5;1(6):219-20. No abstract available.

PMID:
5948326
40.

Post-partum haemorrhage due to quinine.

Simcock MJ, Ungar B, Ekert H.

Med J Aust. 1965 Dec 18;2(25):1023-6. No abstract available.

PMID:
5294939
41.

PAPILLOMAS OF THE UTERINE CERVIX.

Simcock MJ.

Aust N Z J Obstet Gynaecol. 1964 Dec;4(4):174-80. No abstract available.

PMID:
14243041
42.

The catabolism of cytidine 3'-phosphate by rat liver preparations.

SIMCOCK MJ, SNEYD G, BATT RD.

Arch Biochem Biophys. 1957 Sep;71(1):62-8. No abstract available.

PMID:
13459427

Supplemental Content

Loading ...
Support Center